The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized multicenter phase III trial of neoadjuvant gemcitabine + cisplatin + S-1 (GCS) versus surgery first for resectable biliary tract cancer (JCOG1920: NABICAT).
 
Satoshi Nara
No Relationships to Disclose
 
Tatsuya Ioka
Consulting or Advisory Role - Taiho Pharmaceutical
Speakers' Bureau - AstraZeneca; Chugai Pharma; Chugai Pharma; Daiichi Sankyo; Incyte; Kyowa Kirin International; Lilly; Lilly; Merck; MSD; Ono Pharmaceutical; Ono Pharmaceutical; Pfizer; SERVIER; Taiho Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha; Yakult Honsha
Research Funding - Astellas Pharma (Inst); Astellas Pharma (Inst); Eisai (Inst); Eisai (Inst); Incyte (Inst); Incyte (Inst); Taiho Pharmaceutical; Taiho Pharmaceutical
 
Gakuto Ogawa
No Relationships to Disclose
 
Tomoko Kataoka
No Relationships to Disclose
 
Yusuke Sano
No Relationships to Disclose
 
Minoru Esaki
No Relationships to Disclose
 
Hiroaki Nagano
No Relationships to Disclose
 
Masatoshi Kudo
Honoraria - Bayer; Chugai/Roche; Eisai; Lilly Japan; Takeda
Research Funding - Abbvie (Inst); Chugai/Roche; EA Pharma (Inst); Eisai (Inst); GE Healthcare; Otsuka (Inst); Taiho Pharmaceutical (Inst)
 
Masafumi Ikeda
Honoraria - Abbott Laboratories; Abbvie; AstraZeneca; Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; EA Pharma; Eisai; Fujifilm; Incyte; Lilly Japan; MSD; Novartis; Ono Pharmaceutical; SERVIER; Taiho Pharmaceutical; Taisho Pharmaceutical Holdings; Takeda; Teijin Pharma; Yakult Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Eisai; EMD Serono; GlaxoSmithKline; Lilly Japan; MSD; Novartis; Ono Pharmaceutical; SERVIER; Takeda
Research Funding - AstraZeneca (Inst); Bayer Yakuhin (Inst); Bristol-Myers Squibb (Inst); Chiome Bioscience (Inst); Chugai Pharma (Inst); Delta-Fly Pharma (Inst); Eisai (Inst); InVitae (Inst); J-Pharma (Inst); Lilly Japan (Inst); Merck (Inst); Merus NV (Inst); MSD (Inst); Nihon Servier (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Syneos Health (Inst)
 
Masashi Kanai
Stock and Other Ownership Interests - Therabiopharma Inc.
Speakers' Bureau - Chugai Pharma
Research Funding - MolecularHealth
 
Ichiro Yasuda
No Relationships to Disclose
 
Kentaro Yamazaki
Honoraria - Bayer; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Lilly; Merck Serono; MSD; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Taiho Pharmaceutical (Inst)
 
Hirofumi Shirakawa
No Relationships to Disclose
 
Shogo Kobayashi
No Relationships to Disclose
 
Masato Ozaka
Honoraria - AstraZeneca; Bayer; Eisai; MSD; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Naoto Gotohda
No Relationships to Disclose
 
Etsuro Hatano
Honoraria - Abbvie; Bayer; Chugai Pharma; Eisai; Incyte; Lilly; Merck; Ono Pharmaceutical; Otsuka; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Novartis; Shionogi
Research Funding - Eisai; Tsumura & Co.
 
Junji Furuse
Honoraria - Astellas Pharma; AstraZeneca; Bayer Yakuhin; Chugai Pharma; Daiichi Sankyo; EA Pharma; Eisai; Fujifilm; Kyowa Hakko Kirin; Lilly Japan; Merck; MSD; Mylan; Nihon Servier; Novartis; Ono Pharmaceutical; Pfizer; Sanofi; Taiho Pharmaceutical; Takeda; Teijin Pharma; Yakult Honsha
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Chugai Pharma; Eisai; Fujifilm; J-Pharma; Merck; MSD; Mundipharma; OncoTherapy Science; Ono Pharmaceutical; Takara Bio; Yakult Honsha
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Incyte (Inst); J-Pharma (Inst); Merck (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst)
 
Takuji Okusaka
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Incyte; Lilly; Nihon Servier; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - AstraZeneca; Dainippon Sumitomo Pharma; Eisai; FUJIFILM Toyama Chemistry; Nihon Servier
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Incyte; Syneos Health/Immunocore (Inst)
 
Makoto Ueno
Honoraria - AstraZeneca; Chugai Pharma; Incyte; MSD; Novartis; Ono Pharmaceutical; SERVIER; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Novocure
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Chiome Bioscience (Inst); Chugai Pharma (Inst); Delta-Fly Pharma (Inst); Eisai (Inst); Incyte (Inst); JPH Clinical Development (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)